An upscaled extraction protocol for Tasmannia lanceolata (Poir.) A.C. Sm.: Anti-bacterial, anti-Giardial and anticancer activity


Pharmacognosy Communications,2016,6,4,238-254.
Published:August 2016
Type:Original Article

An upscaled extraction protocol for Tasmannia lanceolata (Poir.) A.C. Sm.: Anti-bacterial, anti-Giardial and anticancer activity

Lou Vallette1, 2, Camille Rabadeaux1, 2, Joseph Sirdaarta1,3, Craig Davis4, 5, Ian Edwin Cock1,3*

1Environmental Futures Research Institute, Griffith University, Brisbane, AUSTRALIA.

2School of Biology, Ecole de Biologie Industrielle (EBI), Cergy, FRANCE.

3School of Natural Sciences, Griffith University, Brisbane, AUSTRALIA.

4Botanical Medicine Research Institute, Brisbane, AUSTRALIA.

5Bioextracts P/L, Brisbane, AUSTRALIA.


Background: Tasmannia lanceolata is an endemic Australian plant with a high anti-oxidant capacity. Liquid solvent extractions of T. lanceolata inhibit bacterial growth and block proliferation of several carcinomas and the gastrointestinal parasite Giardia duodenalis. Despite these promising therapeutic properties, methods for the rapid extraction of large quantities of T. lanceolata are lacking. This study aimed to develop a rapid supercritical extraction method to produce extracts which retain therapeutic propertyes and phytochemistry characteristics. Materials and Methods: T. lanceolata fruit and leaf were extracted by both solvent maceration extraction and supercritical fluid extraction (SFE). The extracts were tested for the ability to inhibit bacterial and G. duodenalis growth. Inhibition of CaCo2 and HeLa cancer cells was evaluated using MTS-based colorimetric cell proliferation assays. Toxicity was evaluated using an Artemia franciscana nauplii bioassay and GC-MS headspace analysis was used to evaluate phytochemical similarity between the extracts. Results: T. lanceolata berry and leaf SFEs displayed strong bacterial growth inhibitory activity against bacterial triggers of autoimmune inflammatory diseases, with efficacies similar to the smaller scale liquid solvent extractions. The growth inhibition of the berry SFE was particularly noteworthy against P. mirabilis and K. pneumoniae, with MIC values of approximately 160 and 190 μg/mL, respectively. The berry and leaf SFE extracts also had similar antiproliferative potencies against G. duodenalis (492 and 375 μg/mL, respectively), CaCo2 (4133 and 3347 μg/mL, respectively) and HeLa carcinomas (2652 and 3497 μg/mL, respectively) to those determined for the corresponding liquid solvent extractions. GC-MS analysis of the berry SFE revealed similar terpenoid components and similar abundances to those in liquid solvent berry extraction. Furthermore, all SFEs were either non-toxic or of only low toxicity in the Artemia franciscana toxicity assay. Conclusion: The T. lanceolata SFE retained the tested therapeutic properties, were nontoxic and had similar phytochemical profiles as smaller scale liquid solvent extractions. Thus, SFE is a viable method of rapidly extracting large masses of T. lanceolata plant material to produce quality extracts which retain therapeutic properties.

Founded:  In 2004, as the PHCOG.NET – a non-profit private organization dedicated to Natural Products Research leading to develop promising drugs. Our main mission is to make information on herbal drug research readily available in different formats to suit the individual needs.

Pharmacognosy Communications [Phcog Commn.] is a new quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the  publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.

The journal aims to cater the latest outstanding developments in the field of pharmacognosy and natural products and drug design covering but not limited to the following topics:

  • Pharmacognosy and pharmacognistic investigations
  • Research based ethnopharmacological evaluations
  • Biological evaluation of crude extracts, essential oils and pure isolates
  • Natural product discovery and evaluation
  • Mechanistic studies
  • Method and technique development and evaluation
  • Isolation, identification and structural elucidation of natural products
  • Synthesis and transformation studies

Distinctions:  The most widely read, cited, and known Pharmacognosy Communications and website is well browsed with all the articles published. More than 20,000 readers in nearly every country in the world each month

Aim and Scope | Editorial Board | Indexed & Abstracted | Instruction to Authors | Manuscript Submission & Charges

Subjects Covered : Natural Products, Pharmacognosy, Phytochemistry, Marine Pharmacognosy and Zoo Pharmacognosy
ISSN :2249-0159 (Print) ; 2249-0167 (Online) Frequency : Quarterly Rapid at a time publication (4 issues/year)

Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online  publication is 45 days.
Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.